



Together, improving life

Rev 1: September 2018

FSN Ref: 0000000.11152019.001-R

FSCA Ref: 0000000.11152019.001-R

Date: 18-NOV-2019

Urgent Field Safety Notice
GORE® DrySeal Flex Introducer Sheath

For Attention of*: Healthcare Professionals and/or Hospital Inventory Managers

Contact details of local representative (name, e-mail, telephone, address etc.)*

Claire van den Nieuwenhof
EMEA Regulatory Affairs
W. L. Gore & Associates B.V.
Ringbaan Oost 152-a 5013 CE
Tilburg
The Netherlands
cvandenn@wlgore.com
T +31 135 074 728 M +31 6 29 45 07 26



Rev 1: September 2018

FSN Ref: 0000000.11152019.001-R

FSCA Ref: 0000000.11152019.001-R

Urgent Field Safety Notice (FSN)
 Gore® DrySeal Flex Introducer Sheath
Mislabelled 16Fr Introducer Sheaths
Labelled as 14Fr (3 lots)

1. Information on Affected Devices*	
1	1. Device Type(s)*
.	Sterile Introducer Sheath
1	2. Commercial name(s)
.	GORE® DrySeal Flex Introducer Sheath
1	3. Unique Device Identifier(s) (UDI-DI)
.	Not Applicable
1	4. Primary clinical purpose of device(s)*
.	The GORE® DrySeal Flex Introducer Sheath is intended to be inserted in the vasculature to provide a conduit for the insertion of endovascular devices while minimizing blood loss associated with such insertions.
1	5. Device Model/Catalogue/part number(s)*
.	DSF1433
1	6. Software version
.	Not applicable
1	7. Affected serial or lot number range
.	See "Acknowledgement and Return Form" for lot number(s) identified as sold or in consignment at your location.
1	8. Associated devices
.	Within context of the FSCA – not applicable

2 Reason for Field Safety Corrective Action (FSCA)*	
2	1. Description of the product problem*
.	An incorrect part number on a certificate of conformance sent to Gore resulted in Gore labelling 576 devices with an incorrect product size. All the affected units are labelled as 14Fr but the physical devices are actually 16Fr.
2	2. Hazard giving rise to the FSCA*
.	Hazardous Situation: Sheath being labelled as smaller than it is in actuality when used for the necessary clinical situation. The hub of the sheath and dilator are correctly labelled. Per the IFU, adequate vessel access is required to introduce the sheath into the vasculature. Careful evaluation of vessel size, anatomy, tortuosity, and disease state (including calcification, plaque, and thrombus) is required to ensure successful sheath introduction and subsequent withdrawal. If vessel is not adequate for access, major bleeding, vessel damage,



Rev 1: September 2018

FSN Ref: 0000000.11152019.001-R

FSCA Ref: 0000000.11152019.001-R

	<p>or serious injury to the patient, including death, may result. Hazards are only applicable to the patient, there are no known hazards to the user.</p> <p>The harm associated with this hazard is increased procedural time, injury to, or hemorrhage from, access vessels (e.g., dissection, rupture, perforation, tear, etc.). This is due to the device outer diameter (OD) being larger than anticipated by 0.8 mm. This may result in access vessel damage including dissection, rupture, perforation and tear.</p>
2	3. Probability of problem arising
.	The probability of the hazardous situation arising is very likely. The hazardous situation of the sheaths being larger than expected is true for every device included in this evaluation. While the sheath itself has the correct size marked on the hub and dilator, both the inner and outer packaging is mislabelled.
2	4. Predicted risk to patient/users
.	Low - The hazardous situation in question is not likely to cause adverse health consequences
2	5. Further information to help characterise the problem
.	Not applicable
2	6. Background on Issue
.	In a review of historical documentation received from Gore's contract manufacturer, Gore associates noted that three batches of 16Fr GORE® DrySeal Flex Introducer Sheaths were incorrectly identified as 14Fr, which resulted in 576 units of 16Fr size devices being boxed and labelled as 14Fr devices and released for distribution. Based on the Supplier investigation, there is no indication that product beyond the scope of this FSN is affected. Corrective Actions are being pursued to prevent a recurrence.
2	7. Other information relevant to FSCA
.	None

3. Type of Action to mitigate the risk*	
3.	<p>1. Action To Be Taken by the User*</p> <p> <input checked="" type="checkbox"/> Identify Device <input checked="" type="checkbox"/> Quarantine Device <input checked="" type="checkbox"/> Return Device <input type="checkbox"/> Destroy Device </p> <p> <input type="checkbox"/> On-site device modification/inspection <input type="checkbox"/> Follow patient management recommendations <input type="checkbox"/> Take note of amendment/reinforcement of Instructions For Use (IFU) <input type="checkbox"/> Other <input type="checkbox"/> None </p>



Rev 1: September 2018

FSN Ref: 0000000.11152019.001-R

FSCA Ref: 0000000.11152019.001-R

	All product identified as sold to consignee or in consignment at consignee's location shall be verified as previously used, or if in inventory, shall be returned to Gore. Any returned units shall be replaced. Please follow instructions on the attached "Acknowledgement and Return Form."	
3.	2. By when should the action be completed?	Identify and quarantine as soon as possible Return acknowledgement form and affected devices as soon as possible but no later than 29-NOV-2019.
3.	3. Particular considerations for:	Not applicable
3.	4. Is customer Reply Required? * (If yes, form attached specifying deadline for return)	Yes
3.	5. Action Being Taken by the Manufacturer <input checked="" type="checkbox"/> Product Removal <input type="checkbox"/> On-site device modification/inspection <input type="checkbox"/> Software upgrade <input type="checkbox"/> IFU or labelling change <input checked="" type="checkbox"/> Other <input type="checkbox"/> None Product is to be removed from inventory and returned to the manufacturer for disposition. Corrective Actions are being pursued internally.	
3	6. By when should the action be completed?	Not applicable
3.	7. Is the FSN required to be communicated to the patient /lay user?	No
3	8. If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet?	
	Choose an item.	Choose an item.



Rev 1: September 2018

FSN Ref: 0000000.11152019.001-R

FSCA Ref: 0000000.11152019.001-R

4. General Information*	
4.	1. FSN Type* New
4.	2. For updated FSN, reference number and date of previous FSN Provide reference and date of previous FSN if relevant
4.	3. For Updated FSN, key new information as follows: Summarise any key difference in devices affected and/or action to be taken.
4.	4. Further advice or information already expected in follow-up FSN? * No
4	5. If follow-up FSN expected, what is the further advice expected to relate to: Not applicable
4	6. Anticipated timescale for follow-up FSN Not applicable
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)
	a. Company Name Only necessary if not evident on letter-head.
	b. Address Only necessary if not evident on letter-head.
	c. Website address Only necessary if not evident on letter-head.
4.	8. The Competent (Regulatory) Authority of your country has been informed about this communication to customers. * Competent Authorities of all affected countries have been informed of this communication.
4.	9. List of attachments/appendices: If extensive consider providing web-link instead.
4.	10. Name/Signature Aortic Accessories Product Specialist

Transmission of this Field Safety Notice	
	This notice needs to be passed on all those who need to be aware within your organization or to any organization where the potentially affected devices have been transferred. (As appropriate)
	Please transfer this notice to other organizations on which this action has an impact. (As appropriate)



Together, improving life

Rev 1: September 2018

FSN Ref: 0000000.11152019.001-R

FSCA Ref: 0000000.11152019.001-R

	<p>Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.</p> <p>Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback. *</p>
--	--

Note: Fields indicated by * are considered necessary for all FSNs. Others are optional.



Together, improving life

Rev 1: September 2018

FSN Ref: 0000000.11152019.001-R

FSCA Ref: 0000000.11152019.001-R

Customer Acknowledgement and Return Form

Field Safety Corrective Action (FSCA): 0000000.11152019.001-R / MD175033

Affected Item(s):

Lot/Serial Number	Catalogue Number	Location	Inventory Status (check only one)	
			Used	In Stock
	DSF1433			

Please inspect all inventory for the above lot/serial numbers. Return any identified product for replacement. Please return this form by 29-NOV-2019, even if items are no longer in inventory.

Availability of Affected Item Confirmed: Yes No

Indicate above for each lot/serial number if Item was used or is still in Customer inventory. If not in inventory, but not used – provide explanation:

Retrieval of Affected Item: (If affected item is in Customer Inventory)

- Not Required, Item Used
- Affected Item Removed from Customer's Location

Replacement Order: (Replace only if an item is retrieved and returned)

- Not Required, Item Used
- Replacement Item delivered to customer
- Replacement Item order placed with Customer Service – Order No.: _____

Return of Affected Item:

- Not Required, Item Used, **Return Paperwork only (see below)**
- Affected Item Removed from Customer's Location:

- Ship Device(s) to: **W. L. Gore & Associates
Attn: Rutger Muntjewerf
Dr. Paul Janssenweg 150
5026 RH Tilburg
The Netherlands**

Contact Gore Customer Service for return information



Rev 1: September 2018

FSN Ref: 0000000.11152019.001-R

FSCA Ref: 0000000.11152019.001-R

Person Responsible for Completing Information:

Print Name: _____

Signature:____ Date: _____

Return Paperwork:

- Email Paperwork to: **bfilleru@wlgore.com**
- Or include paperwork with returned devices

It is important that your organisation takes the actions detailed in the FSN and confirms that you have received the FSN.

Your organisation's reply is the evidence we need to monitor the progress of the corrective actions.

=====
=====

Fore Gore Field Sales Associates Only:

Field Sales Associate: _____

Customer Communication Completed on: _____